<u> </u>	MAB	and the second s	Sheet 1 of 25		
		PTO-1449 Modified	Docket No. Serial No. TRU-0005 09/834,321		
		of Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch		
		Department of Commerce nt and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
	OTH	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
*	AA	Ausubel, F.M., et al. (Eds.), Current Sons, Inc., 1994	Protocols in Molecular	Biology, John Wiley &	
MB	AB	Baselga, J., et al., "Recombinant humenhances the antitumor activity of particles overexpressing human breast cancer 2831	clitaxel and doxorubic	in against HER2/neu	
	AC	Bird, R.E., et al., "Single-chain antige 242, 423-426	en-binding proteins," S	Science, October 21, 1988,	
	AD	Boder, E.T., et al., "Yeast surface dis libraries," Nat. Biotechnol., June 199		binatorial polypeptide	
	AE	Bolland, S., et al., "SHIP modulates i membrane association of Btk," <i>Immu</i>			
·	AF	Brooks, D.G., et al., "Structure and exheterogeneity is encoded by the altern <i>Exp. Med.</i> , October 1989 , <i>170</i> , 1369-	natively spliced produc		
	AG	Buchwald, H., et al., "Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis," <i>Surgery</i> , October 1980 , <i>88</i> (4), 507-516			
	АН	Burton, D.R., "Immunoglobulin G: functional sites," Mol. Immunol., 1985, 22(3), 161-206			
	AI	Capel, P.J.A., et al., "Heterogeneity of human IgG Fc receptors," <i>Immunomethods</i> , 1994 , 4, 25-34			
MB	AJ Carter, P., et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy," <i>Proc. Natl. Acad. Sci. USA</i> , May 1992, 89, 4285-4289				
EXAMIN	ER	100	DATE CONSIDERI	ED 10/01/02	

^{*} A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

	Ten.			Sheet 2 of 25	
·	Form	PTO-1449 Modified	Docket No. Serial No. TRU-0005 09/834,321		
	1	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch		
		Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
	ОТНЕ	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
MB	AK	Clackson, T., et al., "Making antibod <i>Nature</i> , August 15, 1991 , <i>352</i> , 624-6		ge display libraries,"	
	AL	Cochet, O., et al., "Intracellular expre Ras promotes tumor regression," Can			
	AM	Cox, A.L., et al., "Identification of a human cytotoxic T cell lines," Science			
	AN	Curiel, D.T., et al., "High-efficiency DNA-polylysine complexes," <i>Hum.</i>			
	AO	Curiel, D.T., "Targeted tumor cytoto oncogene antibodies," Gene Therapy 51-84	xicity mediated by intr Program, Advances in	acellular single-chain anti- Pharmacology, 1997, 40,	
	AP	Daëron, M., "Fc receptor biology," A	Innu. Rev. Immunol., 1	997 , <i>15</i> , 203-234	
÷	AQ	Damen, "The 145-kDa protein inducan inositol tetraphosphate and phosphatase," <i>Proc. Natl. Acad. Sci.</i>	hatidylinositol 3,4,5-tri	isphosphate 5-	
	AR	de Haas, M., et al., "Fcy receptors of 330-341	phagocytes," J. Lab. C	Clin. Med., 1995, 126,	
	AS	AS Deisenhofer, J., "Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution," Am. Chem. Soc., April 28, 1981, 20(9), 2361-2370			
	AT During, M.J., et al., "Controlled release of dopamine from a polymeric brain implanting in vivo characterization," Ann. Neurol., 1989, 25, 351-356			a polymeric brain implant:	
MB	ATI Ellman I et al "Piegymthetic method for introducing unnatural amino acids site-				
EXAMIN	NER	10	DATE CONSIDER	ED	
		- 11 - 11			

				Sheet 3 of 23	
	For	m PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321	
		f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch		
		Department of Commerce nt and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
	отни	ER DOCUMENTS (Including Autho	r, Title, Date, Pertin	ent Pages, Etc.)	
MB	AV	Felgner, P.L., et al., "Cationic liposo 1989, 337, 387-388	me-mediated transfec	tion," <i>Nature</i> , January 26,	
MB	AW	Felgner, P.L., et al., "Lipofection: a liprocedure," Proc. Natl. Acad. Sci. U.	•		
*	AX	Freshney, R.I. (Ed.), Immobilized Ce	ells and Enzymes, IRL	Press, 1986	
	AY	Funakoshi, S., et al., "Differential in anti-CD40 and anti-CD20 monoclong. J. Immunother., 1996, 19(2), 93-101		-	
*	AZ	Gait, M.J. (Ed.), Oligonucleotide Syr	thesis, 1984		
*	BA	Glover, D.N. (Ed.), "DNA Cloning:	A Practical Approach	" Vols. I and II, 1985	
MB	ВВ	Goodson, J.M., in Medical Application	ons of Controlled Rel	ease, 1984 , Vol. 2, 115-138	
*	BC	Hames, B.D., et al. (Eds.), Nucleic A	cid Hybridization, 19	85	
MB	BD	Han, D.C., et al., "Therapy with antisense TGF-β1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice," <i>Am. J. Physiol. Renal Physiol.</i> , 2000 , <i>278</i> , F628-F634			
Hanna, A.K., et al., "Adenoviral-mediated expression of antisense RNA to basic fibroblast growth factor reduces tangential stress in arterialized vein grafts," J. Vasc. Surg., 2000, 31, 770-780					
EXAMINI	ER	1123	DATE CONSIDER	RED 10/01/02	

^{*} A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

(a)		Sheet 4 of 25			
	Orm PTO-1449 M dified	Docket No. TRU-0005			
	st of Patent and Publications Cited by Applicant se several sheets if necessary)	Applicant Jeffrey V. Rave	etch		
	S. Department of Commerce atent and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned		
07	HER DOCUMENTS (Including	Author, Title, Date, Per	rtinent Pages, Etc.)		
MB B	Howard, M.A., et al., "Intracer deficits," J. Neurosurg., 1989,		ts with lesion-induced memory		
В	G Huse, W.D., et al., "Generation immunoglobulin repertoire in 1 1275-1281	_			
B	, , , ,	le-chain Fv analogue pro	neering of antibody binding sites: recovery of specific chain Fv analogue produced in <i>Escherichia coli</i> , ast 1988 , <i>85</i> , 5879-5883		
B	adenocarcinoma recognized an	e, K.R., et al., "Cytotoxic T-lymphocytes derived from patients with breast carcinoma recognized an epitope present on the protein core of a mucin alle preferentially expressed by malignant cells," <i>Cancer Res.</i> , June 1, 1991 , <i>51</i> , 1916			
MB B.	Jones, P.T., et al., "Replacing antibody with those from a mo	_			
*R	K Kabat, et al., "Sequences of Pr Health Service, National Instit	•	· · · · · · · · · · · · · · · · · · ·		
MB B		on of a functional foreign gene in adult mammalian via a herpes simplex virus type 1 defective viral , 1991, 2, 320-330			
B		augh, W.M., et al., "Multiple forms of an inositol polyphosphate 5-phosphatase signaling complexes with Shc and Grb2," <i>Curr. Biol.</i> , 1996 , <i>6(4)</i> , 438-445			
B	N Köhler, G., et al., Nature, Aug	ust 7, 1975 , <i>256</i> , 495-49	7		
BO Kopreski, M.S., et al., "Growth inhibition of breast cancer cell lines by combination of anti-P185 ^{HER2} monoclonal antibody and cytokines," <i>Anticancer Res.</i> , 1996, 16, 433-436					
EXAMINER	183	DATE CONSII	DERED 10/01/02		

^{*} A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

	(A)	Bank Market		Sheet 5 of 25	
	Fori	m PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321	
		f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch		
		Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
	отне	CR DOCUMENTS (Including Autho	r, Title, Date, Pertin	ent Pages, Etc.)	
MB	BP	Langer, R., "New methods of drug do 1527-1533	elivery," <i>Science</i> , Sept	tember 28, 1990 , <i>249</i> ,	
*	BQ	Langer, et al. (Eds.), "Medical Application, Florida, 1974	eations of Controlled	Release," <i>CRC Press</i> , Baca	
MB	BR		physical structure of polymers as carriers for ents: a review," JMS-Rev. Macromol. Chem. Phys.,		
	BS	LaSalle, G.L., et al., "An adenovirus vector for gene transfer into neurons and glia the brain," <i>Science</i> , February 12, 1993 , <i>259</i> , 988-990			
	ВТ	Lebkowski, J.S., et al., "Adeno-associated introduction and integration of DNA and Cell Biol., 1988, 8(10), 3988-399	into a variety of mam		
	BU	Leget, G.A., et al., "Use of rituximab In Oncol., 1998, 10, 548-551	, the new FDA-appro	ved antibody," Curr. Opin.	
	BV	Leung, D.W., et al., "A method for rausing a modified polymerase chain rabio., August 1989 , <i>I(I)</i> , 11-15			
	BW	Levy, R.J., et al., "Inhibition of calcinotrolled-release diphosphonate," S			
	BX	Lewis, G.D., et al., "Differential responses of human tumor cell lines to anti-p185 ^{HER} monoclonal antibodies," <i>Cancer Immunol. Immunother.</i> , 1993 , <i>37</i> , 255-263			
	BY Lopez-Berestein, G., "Treatment of systemic fungal infections with liposomal-amphotericin B," in Liposomal in the Therapy of Infectious Diseases and Cancer, 1989, 317-327				
BZ Liu, J., et al., "Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE," Biochem., 1995, 34, 10474-104					
EXAMIN	ER	1	DATE CONSIDER	RED 10/01/02	

^{*} A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

	.6 5/		Sheet 6 of 25		
FORM	O-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321		
Cite	tent and Publications d by Applicant al sheets if necessary)	Applicant Jeffrey V. Ravetch			
	rtment of Commerce d Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
MB ne	ack, A., et al., "The key role of buty ural disorders: an antisense-5"butyr 00 , <i>60</i> , 607-628				
-1 1 1 1	achy, P., et al., "Gene transfer from etroporation," <i>Proc. Natl. Acad. Sci</i>				
	arasco, W.A., et al., "Intracellular a DS gene therapy," <i>Hum. Gene The</i>	_			
	arks, J.D., et al., "By-passing immusplayed on phage," J. Mol. Biol., 19		dies from V-gene libraries		
fac	asui, H., et al., "Mechanism of antictor receptor monoclonal antibodies ovember 1986 , <i>46</i> , 5592-5598				
	iller, A.D., et al., "Improved retroved oTechniques, 1989, 7(9), 980-990	iral vectors for gene tra	insfer and expression,"		
	ir, L.M., et al., "Long-term, high le ediated gene transfer into skeletal n 9				
fre	CH Morioka, N., et al., "A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-lle-Phe) from human melanoma is recognized by CTL in melanoma patients," <i>J. Immunol.</i> , 1994, 153, 5650-5658				
do	Morrison, S.L., et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> , November 1984 , <i>81</i> , 6851-6855				
	CJ Neuberger, M.S., et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , December 1984 , <i>312</i> , 604-608				
1 44 2 1 1	elsen, P.E., et al., "Sequence-select th a thymine-substituted polyamide	_			
EXAMINER	100	DATE CONSIDERI	ED 10/1/02		

Sheet 7 of 25

		&		Sheet 7 of 25	
	For	m PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321	
		of Patent and Publications Cited by Applicant several sheets if necessary)	Applicant Jeffrey V. Ravetch		
U.S. Department of Commerce Patent and Trademark Office Filing Date April 13, 2001 Not Yet Assigned					
	ОТН	ER DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
MB	CL	Noren, C.J., et al., "A general method amino acids in proteins," Science, Ap	-	-	
	СМ	Ono, M., et al., "Role of the inositol immune system by the receptor FcγR		•	
	CN	Ono, M., et al., "Deletion of SHIP or inhibitory signaling," <i>Cell</i> , July 25, 1		tinct pathways for	
	СО	Pegram, M.D., et al., "Phase II study recombinant humanized anti-p185 ^{HER} patients with HER2/neu-overexpress chemotherapy treatment," <i>J. Clin. On</i>	^{(2/neu} monoclonal antibo ing metastatic breast ca	dy plus cisplatin in ancer refractory to	
V	СР	Peoples, G.E., et al., "HLA-=A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer," <i>J. Immunol.</i> , November 15, 1993 , 151(10), 5481-5491			
*	_ CQ	Perbal, B., A Practical Guide to Mole	ceular Cloning, Ausube	d, F.M., et al. (Eds.), 1984	
MB	Prati, E.G.P., et al., "Engineering of coordinated up- and down-regulation of two glycosyltransferases of the O-Glycosylation pathway in chinese hamster ovary (CHocells," Biotechnol. and Bioeng., May 5, 2000, 68(3), 239-244			ese hamster ovary (CHO)	
	CS Presta,, L.G., "Antibody engineering," Curr. Op. Struct. Biol., 1992, 2, 593-596				
	CT Ravetch, J.V., et al., "Fc receptors," Annu. Rev. Immunol., 1991, 9, 457-492				
MR	CU S	Richardson, J.H., et al., "Intrabody-m receptor in primary human T cells us 1998, 5, 635-644			
EXAM	INER		DATE CONSIDER	ED 10/01/02	

^{*} A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

			Sheet 8 of 25	
FOR	m PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321	
	of Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch		
	Department of Commerce nt and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
ОТНІ	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
MB CV	Riechmann, L., et al., "Reshaping hu 1988, 332, 323-327	man antibodies for the	rapy," <i>Nature</i> , March	
MB CW	Sahasrabudhe, D.M., et al., "Shared tumors," <i>J. Immunol.</i> , December 1, 1	_		
*CX		rook, et al., "Molecular Cloning: A Laboratory Manual," 2 nd Ed., Cold Spring or Laboratory Press, Cold Spring Harbor, NY, 1989		
M/S CY	Samulski, R.J., et al., "A recombinant plasmid from which an infectious adeno- associated virus genome can be excised in vitro and its use to study viral replication," <i>J. Virol.</i> , October 1987 , 61(10), 3096-3101			
CZ	Samulski, R.J., et al., "Helper-free stonormal integration does not require v 63(9), 3822-3828			
DA	Saudek, C.D., et al., "A preliminary to system for insulin delivery," N. Engl.			
DB	Saviranta, P., et al., "Engineering the random mutagenesis and competitive 143-152			
DC	Sefton, M.V., "Implantable pumps," CRC Crit. Rev. Biomed. Eng., England, 1987, 14(3), 201-240			
DD	Shamamian, P., et al., "Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest," <i>Cancer Immunol. Immunother</i> , 1994 , <i>39</i> , 73-83			
V DE MB	Shan, D., et al., "A poptosis of malig monoclonal antibodies," <i>Blood</i> , Marc	· · · · · · · · · · · · · · · · · · ·	-	
EXAMINER	100	DATE CONSIDER	ED 10/01/02	

^{*} A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

	FAD	EMARK OFF	RADEMARK		Sheet 9 of 25
	Fo	rm PTO-1449 N		Docket No. TRU-0005	Serial No. 09/834,321
		of Patent and Pu Cited by Appli several sheets if	cant	Applicant Jeffrey V. Ravetch	
		Department of Cent and Tradema		Filing Date April 13, 2001	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date					nt Pages, Etc.)
*	DF		. (Eds.), "Controlled D " <i>Wiley</i> , NY, 1984	rug Bioavailability, Dru	ig Product Design and
MU	b DG	DG Stratford-Perricaudet, L.D., et al., "Widespread long-term gene transfer to mouse skeletal muscles and heart," J. Clin. Invest., August 1992, 90, 626-630			
1	Taji, H., et al., "Growth inhibition of CD20-positive B lymphoma cell lines by ID C2B8 anti-CD20 monoclonal antibody," <i>Jpn. J. Cancer Res.</i> , July 1998 , <i>89</i> , 748-				
	DI		nl., "Augmented humor e, January 25, 1996 , <i>37</i>		ponses in FcyRll-deficient
	DJ		al., "FcRγ chain deletio y 11, 1994 , <i>76</i> , 519-529		e effector cell defects,"
	DK	1	ouse variable and huma	himaeric processed imi un constant region seque	nunoglobulin genes ences," <i>Nature</i> , April 4,
	DL		rials," in Liposomes in		ninary results of phase 1 us Disease and Cancer,
	DM Tutt, A.L., et al., "Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors," J. Immunol., 1998, 161, 3176-3185				mphoma: signaling nent of effectors," <i>J</i> .
	DN Ulmer, J.B., et al., "Heterologous protection against influenza by injection of DNA encoding a viral protein," <i>Science</i> , March 19, 1993 , 259, 1745-1749				
Waldmann, T.A., "Lymphokine receptors: a target for immunotherapy of lymphomas," Ann. Oncol., 1994, 5 Supp. 1, S13-S17					
EXAM	IINER	1000		DATE CONSIDER	ED 10/01/02
					

^{*} A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

Sheet 10 of 25

г		DEW AND CO.		Sheet 10 of 25		
	For	m PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321		
		f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch			
2		Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned		
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
MB	DP	Ward, E.S., et al., "The effector functions therapy," <i>Therapeutic Immunol.</i> , 199		ins: implications for		
	DQ	Ward, E.S., et al., "Binding activities variable domains secreted from <i>Esche</i> 544-546		•		
	DR	Williams, R.S., et al., "Introduction of DNA-coated microprojectiles," <i>Proc.</i> 2726-2730				
	DS	Wilson, J.M., "Hepatocyte-directed gene transfer <i>in vivo</i> leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits," <i>J. Biol. Chem.</i> , January 15, 1992 , 267(2), 963-967				
	DT	Wu, G.Y., et al., "Receptor-mediated carriers system," J. Biol. Chem., April				
	DU	Wu, G.Y., et al., "Receptor-mediated <i>Chem.</i> , October 15, 1988 , 263(29), 14		ression in vivo," J. Biol.		
	DV	Yang, C., et al., "Antisense suppressichemosensitivity in human prostate,"				
	Yang, L., et al., "Expression of <i>ERCC1</i> antisense rna abrogates gemcitabine-mediate cytotoxic synergism with cisplatin in human colon tumor cells defective in mismate repair but proficient in nucleotide excision repair," <i>Clin. Cancer Res.</i> , March 2000, 773-781					
	Yuan, R., et al., "Antibody-mediated modulation of cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclasses," J. Exp. Med., February 16, 1998, 187(4), 641-648					
,	DY	Lin, S., et al., "Giving inhibitory rece	ptors," <i>Science</i> , Janaur	y 19, 2001 , <i>291</i> , 445-446		
MB	DZ Samuelsson, A., et al., "Anti-inflammatory activity of IVIG mediated through the					
EXAMINI	ER	13	DATE CONSIDERI	ED 10/01/03		
	11					

r	Sheet 11 of 25				
	For	m FTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321	
		f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch		
		Department of Commerce nt and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
	ОТН	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
MB	EA	Allan, R., et al. "Studies on the comp G-I. Modification of tryptophan resid of rabbit IgG" <i>Immunochemistry</i> , 197	ues and their role in ar	_	
	ЕВ	Angal, S., et al., "A single amino acid chimeric mouse/human (IgG4) antibo			
	EC	Armour, K.L., et al., "Recombinant h binding and monocyte triggering activates" 29(8), 2613-2624	_		
	ED	Bloom, J.W., et al., "Intrachain disul IgG4" <i>Protein Science</i> , 1997 , <i>6</i> , 407-4		inge region of human	
	EE	Bredius, R.G.M., et al., "Role of neut Fc\147\norRIIIb (CD16) polymorphic IgG3-opsonized bacteria and erythrod	forms in phagocytosis	s of human IgG1- and	
	EF	Brekke, O.H., et al., "Human IgG iso complement-mediated cell lysis and p 1994, 24(10), 2542-2547		_	
	EG	Burmeister, W.P., et al., "Crystal struwith Fc" <i>Nature</i> , 1994, 372(6504), 37		of rat neonatal Fc receptor	
	ЕН	Burton, D.R., et al., "Molecular reco (FcRI)" Molecular Immunology, 1988		G) by cellular Fc receptor	
	EI Burton, D.R., et al., "The Clq receptor site on immunoglobulin G" Nature, 1980, 288(5789), 338-344				
MI	EJ	Burton, D.R., "Human antibody effect 1-84	etor function," Advance	es in Immunol., 1992 , 51,	
EXAM	INER	108	DATE CONSIDER	ED 10/01/02	

Sheet I					
	Fori	m PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321	
		f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch		
		Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
	ОТНЕ	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
MB	EK	Canfield, S.M., et al., "The binding a receptor is determined by multiple an modulated by the hinge region" <i>Journ</i> 1483-1491	nino acids in the C\sub	H\nor2 domain and is	
	EL	Capon, D.J., et al., "Designing CD4 1989, 337, 525-531	Immunoadhesins for A	AIDS Therapy" Nature,	
	ЕМ	Chappel, M.S., et al., "Identification Genetically Engineered Human IgG A 1993, 268, 25124-25131	- ,	~	
	EN	Chappel, M.S., et al., "Identification IgG through the use of recombinant I Proc. Natl. Acad. Sci. USA, 1991, 88	gG1/IgG2 hybrid and p		
	ЕО	Clynes, R., et al., "Cytotoxic antibodi <i>Immunity</i> , 1995 , <i>3</i> (<i>1</i>), 21-26	es trigger inflammatio	n through Fc receptors"	
	EP	Clynes, R., et al., "Fc receptors are re melanoma" <i>Proc. Natl. Acad. Sci. US</i>	-	-	
EQ Clynes, R., et al., "Modulation of immune complex-induced inflammation in vivo the coordinate expression of activation and inhibitory Fc receptors" <i>Journal of Experimental Medicine</i> , 1999 , <i>189(1)</i> , 179-185				<u> </u>	
	ER Clynes, R., et al., "Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis" <i>Science</i> , 1998 , <i>279</i> (5353), 1052-1054				
	ES Cosimi, A.B., "Clinical Development of ORTHOCLONE OKT3" Transplantation Proceedings, 1987, (Suppl 1) XIX(2), 7-16				
Duncan, A.R., et al., "Localization of the binding site for the human high-affinity FC receptor on IgG" Nature, 1988, 332, 563-564					
EXAMINE	ER	10	DATE CONSIDER	ED 10/01/02	

٠.		SE	DIPEES S			
		Forr	n PTO-1449 Modified	Docket No. TRU-0005	Sheet 13 of 25 Serial No. 09/834,321	
		(f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch		
•			Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
		OTHE	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
MB	1	EU	Duncan, A.R., et al., "The binding sit	e for Clq on IgG" Nati	ure, 1988, 332, 738-740	
	EV Gazzano-Santoro, H., et al., "A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody" <i>Journal of Immunological Methods</i> , 1997 202, 163-171					
		EW	Gergely, J., et al., "Fc receptors on ly Transactions, 1984, 12(5),739-743	mphocytes and K cells	" Biochemical Society	
		EX	Ghebrehiwet, B., et al., "Isolation, cD surface glycoprotein that binds to the Experimental Medicine, 1994, 179(6)	globular "heads" of C		
		EY	Ghetie, V., et al., "FcRn: the MHC cl transporter" <i>Immunology Today</i> , 199	-	hat is more than an IgG	
		EZ	Ghetie, V., et al., "Abnormally short serum half-lives of IgG in/1422-microglobulin-deficient mice" <i>European Journal of Immunology</i> , 1996 , 26(3), 690-696			
		FA	Ghetie, V., et al., "Increasing the seru mutagenesis" <i>Nature Biotechnology</i> ,	-	G fragment by random	
		FB	Gorman, C.M., et al., "Transient Prod Transformed Cell Line" <i>DNA Prot. E</i>			
		FC	Graham, F.L., et al., "Characteristics from Human Adenovirus Type 5" J.			
		FD	Greenwood, J., et al., "Engineering m CAMPATH-1H: effects on complem 247-255			
		FE	Greenwood, J., et al., "Structural mofunctions" European Journal of Imm			
MB		FF	Guddat, L.W., et al., "Three-dimension hinge deletion" PNAS (USA), 1993, 9		nan immunoglobulin with a	
EXAM	INI	ER	100	DATE CONSIDER	ED 10/1/02	

	\\a_{\n}			Sheet 14 of 25	
	Fori	TO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321	
		f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch	2	
		Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
	ОТНЕ	CR DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
MB	FG	Haagen, I., et al., "Interaction of Hun A New Indicator for the Fc\147RIIa (154, 1852-1860			
	FH	FH Hadley, A.G., et al., "The functional activity of Fc\147RII and Fc\147RIII on subset of human lymphocytes" <i>Immunology</i> , 1992, 76(3),446-451			
	FI	FI Harris, L.J., et al., "Crystallographic Structure of an Intact IgG1 Monoclonal Antibody" <i>Journal of Molecular Biology</i> , 1998 , 275, 861-872			
	FJ	Harris, L.J., et al., "Refined Structure of an Intact IgG2a Monoclonal Antibody" Biochemistry, 1997, 36, 1581-1597			
	FK	Hatta, Y., et al., "Association of Fc\147 receptor IIIB, but not of Fc\147 receptor IIA and IIIA, polymorphisms with systemic lupus erythematosus in Japanese" <i>Genes and Immunity</i> , 1999 , <i>1</i> , 53-60			
	FL	Heiken, H., et al., "T lymphocyte development in the absence of Fc\145 receptor I\14 subunit: analysis of thymic-dependent and independent \141\142 and \147\144 pathways" <i>European Journal of Immunology</i> , 1996 , <i>26(8)</i> , 1935-1943			
	FM Henry, A.J., et al., "Participation of the N-terminal region of C\1453 in the binding human IgE to its high-affinity receptor F\145RI" <i>Biochemistry</i> , 1997 , 36, 15568-15578			of C\1453 in the binding of try, 1997 , 36,	
	FN Hogarth, P.M., et al., "Characterization of FcR Ig-binding sites and epitope mapping" Immunomethods, 1994, 4(1), 17-24			ites and epitope mapping"	
	FO	Huizinga, T.W.J., et al, "Binding Chato Human Neutrophils" Journal of In	aracteristics of Dimerion aracteristics of Dimerion 1989, 142	c IgG Subclass Complexes 2, 2359-2364	
MB	Hulett, M.D., et al., "Chimeric Fc Receptors Identify Functional Domains of the Murine High-Affinity Receptors for IgG" J. Immunol., 1991, 147, 1863-1868				
EXAMIN	NER	Caro	DATE CONSIDER	ED 10/01/02	
				, ,	

/	DIPER	
	SEP 0 7 2001	
18	TA MADE WATER	

	Fori	n PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321	
		f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch		
		Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
	отни	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
MB	FQ	Jaakkola, K., et al., "In vivo detection inflammation" American Journal of It			
	FR	Janeway et al. Immunobiology, The land Garland Publishing Inc., NY & I			
	FS	Jefferis, R., et al., "Molecular Definit Receptors (huFc\147R)" <i>Molecular I</i>		· · · · · · · · · · · · · · · · · · ·	
	FT	Kabat, E. et al. Sequences of Proteins of Immunological Interest, 5th edition, Bethesda, MD:NIH, 1991, Vol. 1, 669, 671, 687, 696			
	FU	Kim, J.K., et al., "Catabolism of the Murine IgG1 Molecule: Evidence That Both CH2-CH3 Domain Interfaces are Required for Persistence of IgG1 in the Circulation of Mice" Scandinavian Journal Of Immunology, 1994, 40(4), 457-465			
	FV		Kim, J.K., et al., "Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis" <i>European Journal of Immunology</i> , 1994 , <i>24</i> , 542-548		
	FW	Kim, J.K., et al., "Inhibition of Vascu Angiogenesis Suppresses Tumour Gr			
	FX Kim, J.K., et al., "Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor" European Journal of Immunology, 1994, 24, 2429-2434				
	FY	Kim, K.J., et al., "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies" <i>Growth Factors</i> , 1992, 7(1), 53-64			
nus	FZ	Koene, H.R., et al., "FcγRIIIa-158V/IgG by Natural Killer Cell Fc\147RII Phenotype" <i>Blood</i> , 1997 , <i>90(3)</i> ,1109	IIa, Independently of th		
EXAMIN	ER	Pas	DATE CONSIDER	ED 10/0/02	

	PAR	EMARK OFF.		Sheet 16 of 25	
	_	n PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321	
	(Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch		
		Department of Commerce t and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
	ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
MB	GA	Kunkel, T.A., "Rapid and Efficient S Selection" <i>Proc. Natl. Acad. Sci.</i> , 198	-	sis Without Phenotypic	
	GB	Lauvrak, V., et al., "Identification and displayed peptides" <i>Biological Chem</i>			
	GC	Lehrnbecher, T., et al., "Variant geno of Kaposi's sarcoma in HIV-infected	otypes of Fc\147RIIIA influence the development men" <i>Blood</i> , 2000 , <i>95(7)</i> , 2386-2390		
	GD Lehrnbecher, T., et al., "Variant genotypes of the low-affinity Fc\147 receptors in two control populations and a review of low-affinity Fc\147 receptor polymorphisms in control and disease populations" <i>Blood</i> , 1999, 94(12), 4220-4232			eptor polymorphisms in	
	GE	Li, M., et al., "Reconstitution of human Fc\147RIII cell type specificity in transgenic mice" Journal of Experimental Medicine, 1996, 183(3), 1259-1263			
	GF	Lifely, M.R., et al., "Glycosylation ar expressed in different cell lines and g Glycobiology, 1995, 5(8), 813-822			
	GG	Lorenz, A., "Strong association betw recurrent spontaneous abortion," Eur			
	GH	Lucas, B.K., et al., "High-level produ a dicistronic DHFR intron expression 1774-1779			
	GI	Lund, J., et al., "Human Fc\147\norRI and Fc\147\nor RII interact with distinct but overlapping sites on human IgG" <i>Journal of Immunology</i> , 1991 , <i>147(8)</i> , 2657-2662.			
GJ Lund, J., et al., "Multiple binding sites on the C\subH\nor2 domain of IgG for more Fc\147\norR11" Molecular Immunology, 1992, 29(1), 53-59					
EXAMIN	ER	100	DATE CONSIDER	ED 10/01/02	
		-		, ,	

2			Sheet 17 of 25	
\ 4	TO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321	
C	Cited by Applicant	Applicant Jeffrey V. Ravetch		
		Filing Date April 13, 2001	Group Not Yet Assigned	
THE	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
SK	Lund, J. et al., "Multiple Interactions of the IgG with Its Core Oligosaccharide Can Modulate Recognition by Complement and Human Fc\147 Receptor I and Influence the Synthesis of Its Oligosaccharide Chains" J. Immunol., 1996, 157, 4963-4969			
EL			can modulate recognition	
SM				
GN Medesan, C., et al., "Delineation of the amino acid residues involved in transcytos and catabolism of mouse IgG1" <i>Journal of Immunology</i> , 1997 , <i>158(5)</i> , 2211-2217			involved in transcytosis 97 , <i>158(5)</i> , 2211-2217	
Ю	Medesan, C., et al., "Localization of the site of the IgG molecule that regulates maternofetal transmission in mice" <i>European Journal of Immunology</i> , 1996 , 26(10), 2533-2536			
SP				
GQ				
GR Morgan, A., et al., "The N-terminal end of the C\subH\nor2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc\147\norRI and Fc\147\norRIII binding" <i>Immunology</i> , 1995, 86(2), 319-324				
SS	Morrison, S.L. et al., "Structural Dete Immunologist, 1994, 2, 119-124	erminants of Human Ig	gG Function"	
Nagarajan, S., et al., "Ligand binding and phagocytosis by CD16 (Fc \147\nor reception III) isoforms. Phagocytic signaling by associated \172\nor and \147\nor subunits in Chinese hamster ovary cells" Journal of Biological Chemistry, 1995, 270(43), 25762-25770				
	12	DATE CONSIDER	ED 12/01/02	
	ist of Case see S. De atente FHE S. De a	ist of Patent and Publications Cited by Applicant se several sheets if necessary) S. Department of Commerce Patent and Trademark Office THER DOCUMENTS (Including Author K Lund, J. et al., "Multiple Interactions Modulate Recognition by Complement the Synthesis of Its Oligosaccharide of of I	Docket No. TRU-0005 Applicant Set of Patent and Publications Cited by Applicant Set several sheets if necessary) S. Department of Commerce Patent and Trademark Office THER DOCUMENTS (Including Author, Title, Date, Pertinent of Modulate Recognition by Complement and Human Fc\\(^147\) the Synthesis of Its Oligosaccharide Chains'' J. Immunol., 1 Lund, J., et al., "Oligosaccharide-protein interactions in IgG by Fc\\(^147\) receptors'' FASEB Journal, 1995, 9, 115-119 M Medesan, C., et al., "Comparative studies of rat IgG to furth interaction site'' European Journal of Immunology, 1998, 2. M Medesan, C., et al., "Delineation of the amino acid residues and catabolism of mouse IgG1'' Journal of Immunology, 1988, 2. M Medesan, C., et al., "Localization of the site of the IgG molmaternofetal transmission in mice'' European Journal of Immunology, 198, 2. Meng, Y.G., et al., "Green fluorescent protein as a second s selection of high producing clones from transfected CHO oc 201-207 Miller, K.L., et al., "A Novel Role for the Fc Receptor \147 the Fc\147R Ligand Affinity'' Journal of Experimental Mea 2227-2233 Morgan, A., et al., "The N-terminal end of the C\subH\nor2 human IgG1 anti-HLA-DR is necessary for C1q, Fc\147\no binding'' Immunology, 1995, 86(2), 319-324 Morrison, S.L. et al., "Structural Determinants of Human Ig Immunologist, 1994, 2, 119-124 Nagarajan, S., et al., "Iligand binding and phagocytosis by GIII) isoforms. Phagocytic signaling by associated \172\nor a Chinese hamster ovary cells'' Journal of Biological Chemis 25762-25770	

	PARTE	TO A SECOND PROPERTY.		Sheet 18 of 25
	Forn	n PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321
	•	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch	
		Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned
	ОТНЕ	CR DOCUMENTS (Including Author	or, Title, Date, Pertine	nt Pages, Etc.)
MB	GU	Ngo, J.T., et al., "Computational Co Levinthal Paradox" The Protein Fold Merz & Le Grand, Boston:Birkhaus	mplexity, Protein Struc ding Problem and Tert	ture Prediction, and the
GV Nieto, A., et al., "Involvement of the Fc\147 receptor IIIA genotypes to rheumatoid arthritis" <i>Arthritis and Rheumatism</i> , 2000, 43(4), 735-				genotypes in susceptibility 3(4), 735-739
	GW Okada, H., et al., "Cutting Edge: Role of the inositol phosphatase SHIP in B receptor-induced Ca\sup2+\nor oscillatory response" Journal of Immunology, 161(10), 5129-5132			
	GX	Papac, D.I., et al., "A high-throughp oligosaccharide from glycoproteins time-of-flight mass spectrometric ar	for matrix-assisted lase	r desorption/ionization
	GY	Papac, D.I., et al., "Analysis of Acid Matrix-Assisted Laser Desorption/Io Anal. Chem., 1996, 68, 3215-3223	lic Oligosaccharides an onization Time-of-Fligh	d Glycopeptides by ht Mass Spectrometry"
	GZ	Popov, S., et al., "The stoichiometry fragments with the MHC class I-rela 33(6), 521-530	and affinity of the intented receptor, FcRn" M	eraction of murine Fc colecular Immunology, 1990
	НА	Porges, A.J., et al., "Novel Fc\147 R Mononuclear Cells" J. Clin. Invest.,	Receptor I Family Gene 1992, 90, 2102-2109	Products in Human
	НВ	Presta, L.G., et al., "Humanization of Monoclonal Antibody for the Thera Research, 1997, 57(20), 4593-4599	py of Solid Tumors and	dothelial Growth Factor d Other Disorders" Cancer
	НС	Raghavan, M., et al., "Fc Receptors Annu. Rev. Cell. Dev. Biol., 1996,	and their Interactions v 12, 181-220	with Immunoglobulins"
V	HD	Raghavan, M., et al., "Analysis of the recentor/immunoglobulin G interactions."	he pH dependence of the	ne neonatal Fc

EXAMINER DATE CONSIDERED 10/01/02

Biochemistry, 1995, 34(45), 14649-14657

MB

receptor/immunoglobulin G interaction using antibody and receptor variants"



			1	
	Fr	n PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321
	•	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch	
		Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned
	ОТНЕ	CR DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)
MB	HE	Ravetch, J.V., et al., "Divergent roles Annual Review of Immunology, 1998		complement in vivo"
	HF	Ravetch, J.V., "Fc receptors" Current	t Opinion in Immunolo	оду, 1997 , <i>9(1)</i> :121-125
	HG	Ravetch, J.V., "Fc receptors: rubor re	dux" <i>Cell</i> , 1994 , 78(4)), 553-560
	нн	Reff, M.E., et al., "Depletion of B ce monoclonal antibody to CD20" Blood		
	НІ	Sarmay, G., et al., "Ligand inhibition studies on the role of Fc receptors in antibody-dependent cell-mediated cytotoxicity" <i>Molecular Immunology</i> , 1984 , 21(143-51		
	НЈ	Sarmay, G., et al., "Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc\147\nor receptor" <i>Molecular Immunology</i> , 1992 , 29(5), 633-639		
	нк	Sensel, M.G., et al., "Amino acid diffinfluence the relative abilities of IgG <i>Immunology</i> , 1997 , <i>34(14)</i> ,1019-102	2 and IgG3 to activate	
	HL Shores, E.W., et al., "T cell development in mice lacking all T cell receptor \172 family members (\172, \150, and Fc\145RI\147)" Journal of Experimental Medic 1998, 187(7), 1093-1101			
	НМ	Sondermann, P., et al., "Crystal structure of the soluble form of the human Fc\147-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution" <i>EMBO Journal</i> , 1999 , <i>18(5)</i> , 1095-1103		
MB	HN	Sondermann, P., et al., "The 32-A cry Fragment-Fc\147RIII complex" <i>Natu</i>		
EXAMIN	VER	100	DATE CONSIDER	ED 19/01/02

SEP 1	E CAS		
ATTEN &	TO APPLE PARTY		Sheet 20 of 25
For	n PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321
	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch	
	Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned
ОТНЕ	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)
муз но	Strohmeier, G., et al., "Neutrophil fur valency" Journal of Leukocyte Biolog		
НР	Strohmeier, G.R., et al., "Role of the Fc\147\norRIII in the activation of hu immune complexes" <i>Journal of Leuk</i>	man neutrophils by lo	w and high valency
HQ	Suzuki, Y., et al., "Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis" <i>Kidney International</i> , 1998 , <i>54(4)</i> , 1166-1174		
HR	Sylvestre, D.L., et al., "A dominant recreaction" <i>Immunity</i> , 1996 , <i>5(4)</i> , 387-3		eptors in the Arthus
HS	Sylvestre, D.L., , "Fc receptors initiating inflammatory cascade" <i>Science</i> , 1994		
нт	Sylvestre, D., et al., "Immunoglobuli normally in complement-deficient mines 184(6), 2385-2392		
HU	Tamm, A., et al., "The IgG binding some CC' and FG loops of the membrane-parameter, 1996, 271(7), 3659-3666		
HV	Tao, M., et al., "Structural features of isotype-specific differences in complementaries, 1993, 178(2), 661-667		
HW	Tao, M., et al., "Studies of aglycosyla Carbohydrate in the Structure and Ef Constant Region" <i>Journal of Immuno</i>	fector Functions Media	ated by the Human IgG
MB HX	Tao, M., et al., "The differential abilicomplement is determined by the CO domain" Journal of Experimental Me	OH-terminal sequence	e of the C\subH\nor2
EXAMINER	103	DATE CONSIDER	ED 19/61/02



Fori	n PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321	
	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch	·	
	Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned	
ОТНЕ	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
М/З	Tax, W.J.M., et al., "Fc receptors for polymorphism and role in antibody-in <i>Immunology</i> , 1984 , <i>133(3)</i> , 1185-118	nduced T cell prolifera	=	
HZ	Ting, A.T., et al., "Fc\147 receptor activation induces the tyrosine phosphorylation of both phospholipase C (PLC)-\1471 and PLC-\1472 in natural killer cells" <i>Journal of Experimental Medicine</i> 1992 , <i>176(6)</i> , 1751-1755			
IA	Umana, P., et al., "Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity" <i>Nature Biotechnology</i> , 1999 , <i>17</i> , 176-180			
IB	Urfer, R., et al., "High resolution mapping of the binding site of TrkA for nerve growth factor and TrkC for neurotrophin-3 on the second immunoglobulin-like domain of the Trk receptors" <i>Journal of Biological Chemistry</i> , 1998 , <i>273(10)</i> , 5829-5840			
IC	· -	Van de Winkel, J.G.J., et al., "Biology of human immunoglobulin G Fc receptors" Journal of Leukocyte Biology, 1991, 49(5), 511-524		
ID				
IE	Warmerdam, P.A.M., et al., "A single amino acid in the second Ig-like domain of the human Fc\147\nor receptor II is critical for human IgG2 binding" <i>Journal of Immunology</i> , 1991 , <i>147(4)</i> , 1338-1343			
IF	Weng, Z., et al., "Computational determine neonatal Fc receptor" Journal of Mol			
MB IG	Werther, W.A., et al., "Humanization Antigen (LFA)-1 Monoclonal Antibo Antibody for Binding to Rhesus LFA	dy and Reengineering	of the Humanized	
EXAMINER	PAT	DATE CONSIDER	ED 10/0/02	

Sheet 22 of 25

		RASEMAN	<u> </u>	Sneet 22 of 25		
	Forr	n PTO-1449 Modified	Docket No. TRU-0005	Serial No. 09/834,321		
		f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Jeffrey V. Ravetch			
		Department of Commerce at and Trademark Office	Filing Date April 13, 2001	Group Not Yet Assigned		
	OTHE	CR DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)		
MB	IH	Woof, J.M., et al., "Localisation of the immunoglobulin G" <i>Molecular Immu</i>		_		
	II	Wright, A., et al.,, "Effect of altered C\subH\nor2-associated carbohydrate structure the functional properties and in vivo fate of chimeric mouse-human immunoglobut G1" <i>Journal of Experimental Medicine</i> , 1994 , <i>180</i> (3), 1087-1096				
	IJ	Wu, J., et al., "A novel polymorphism of Fc\147RIIIa (CD16) alters receptor functio and predisposes to autoimmune disease" <i>Journal of Clinical Investigation</i> , 1997 , 100(5), 1059-1070				
	IK	Xu, Y., et al., "The N-terminal sequence of the C\subH\nor2 domain controls the differential ability of human IgG1 and IgG2 to activate complement" <i>Journal of Immunology</i> , 1993 , (abstract no. 862), 150(8), 152A				
IL Yap S., et al., "Human Fc gamma receptor IIA (Fc\147RIIA) genotyping and association with systemic lupus erythematosus (SLE) in Chinese and Malay Malaysia" Lupus, 1999, 8(4), 305-310						
EXAMINE	ER		DATE CONSIDER	ED 10/01/02		

Sheet 23 of 25

Form PTO-1449 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Docket No.
TRU-0005

Serial No. **09/834,321**

Applicant

Jeffrey V. Ravetch

Filing Date
April 13, 2001

Group

Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner Initial	1	Document No.	Date	Name	Class	Subclass
MB	IM	4,816,567	03/28/89	Cabilly, et al.	530	387
	IN	4,946,778	08/07/90	Ladner, et al.	435	69.6
	Ю	5,034,506	07/23/91	Summerton, et al.	528	391
	IP	5,132,405	07/21/92	Huston, et al.	530	387.3
	IQ	5,459,127	10/17/95	Felgner, et al.	514	7
	IR	5,476,786	12/19/95	Huston	435	252.33
	IS	5,554,601	09/10/96	Simpkins, et al.	514	182
	IT	5,580,859	12/03/96	Felgner, et al.	514	44
	IU ·	5,589,466	12/31/96	Felgner, et al.	514	44
	IV	5,624,821	04/29/97	Winter, et al.	435	69.6
	IW	5,637,684	06/10/97	Cook, et al.	536	23.1
	IX	5,677,437	10/14/77	Teng, et al.	536	23.1
	IY	5,773,231	06/30/98	Medford, et al.	435	7.24
_	IZ	5,780,607	07/14/98	Goodnow, Jr., et al.	536	22.1
	JA	5,783,682	07/21/98	Cook, et al.	536	24.3
	JB	5,792,844	08/11/98	Sanghvi, et al.	536	23.1
	JC	5,811,234	09/22/98	Roninson, et al.	435	6
	JD	5,814,500	09/29/98	Dietz	435	172.3
	JE	5,834,597	11/10/98	Tso, et al.	530	387.3
MB	JF	5,981,229	11/09/99	Masure, et al.	435	69.3
EXAMINER			DATE CONSIDER	DATE CONSIDERED 10/01/02		

		RADEMARK OFF			She	eet 24 of 25
Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				Docket No. TRU-0005	Serial No. 09/834,321	
				Applicant Jeffrey V. Ravetch		
U.S. Department of Commerce Patent and Trademark Office			Filing Date April 13, 2001			
		U. S	S. PATENT DO	CUMENTS		
Examiner Initial		Document No.	Date	Name	Class	Subclass
MB	JG	5,648,260	07/15/97	Winter, et al.	435	252.3
	ЈН	4,752,601	06/21/88	Hahn	514	14
	Л	5,348,876	09/20/94	Michaelsen, et al.	435	240.2
	JJ	5,624,821	04/29/97	Winter, et al.	435	69.6
	JK	5,648,260	07/15/97	Winter, et al.	435	252.3
	JL	5,698,449	12/16/97	Baumann, et al.	436	507
	JM	5,736,137	04/07/98	Anderson, et al.	424	133.1
	JN	5,985,599	11/16/99	McKenzie, et al.	435	69.1
	JO	US 6,194,551 B1	02/27/01	Idusogie, et al.	530	387.1
	JP	09/483,588	01/14/00	Presta		
MB	JQ	09/713,425	11/15/00	Presta		
		FORE	IGN PATENT	DOCUMENTS	- 	
Examiner Initial		Document No.	Date	Country	Translation YES NO	
MB	JR	2,012,311	09/16/90	Canada		
	JS	WO 86/01533	03/13/86	PCT		
	JT	WO 88/07089	09/22/88	PCT		
	JU	WO 89/07142	08/10/89	PCT		
	JV	WO 92/05263	04/02/92	PCT		
	JW	WO 94/21807	09/29/94	PCT		
	JX	WO 95/05468	02/23/95	PCT		
MOS	JY	WO 95/18863	07/13/95	PCT	X abst ract	<u> </u>
EXAMINER (1)			DATE CONSIDE	RED 10/0	102	

Sheet 25 of 25

Form	PTO-1449	Modified		

Docket No. TRU-0005

Serial No. 09/834,321

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

Applicant Jeffrey V. Ravetch

U.S. Department of Commerce

Filing Date

Group

	Patent	and Trademark Office	ce	April 13, 2001	Not Yet Assigned		
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation YES NO		
MB	JZ	WO 95/21931	08/17/95	PCT	X abstract		
	KA	WO 95/28494	10/26/95	PCT			
	KB	WO 96/17823	06/13/96	PCT	X abstract		
	KC	WO 96/25508	08/22/96	PCT	X abstract		
	KD	WO 98/05787	02/12/98	PCT			
	KE	WO 98/23289	06/04/98	PCT			
	KF	WO 99/01157	01/14/99	PCT	X abstract		
	KG	WO 99/01158	01/14/99	PCT	X abstract		
	KH	WO 99/01175	01/14/99	PCT			
	KI	WO 99/51642	10/14/99	PCT			
	KJ	WO 00/09560	02/24/00	PCT			
	KK	WO 88/07089	09/22/88	PCT			
	KL	WO 94/29351	12/22/94	PCT			
	KM	WO 97/28267	08/07/97	PCT			
	KN	WO 97/44362	11/27/97	PCT			
	ко	WO 98/23289	06/04/98	PCT			
	KP	WO 98/52975	11/26/98	PCT	X abstract		
	KQ	WO 99/43713	09/02/99	PCT			
MUS	KR	WO 99/58572	11/18/99	РСТ			
EXAMINE	R	100		DATE CONSIDE	RED 10/0/02		